Zydus and Synthon ink licensing and supply agreement for Ozanimod Capsules for US market
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
Zydus MedTech gets rights to market the innovative Transcatheter Aortic Valve Implantation (TAVI) technology in India, Europe and other select markets
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
The pooled prevalence of GERD in the Indian population is 15.6 %
Subscribe To Our Newsletter & Stay Updated